R.s. Duncanson

R.S. Duncanson has a strong background in engineering and research. They began their career as a Research Engineer Intern at Kansai Paint Company Ltd in 2006. They then worked as a Research Intern at MIT, where they tested the efficacy of nano-particle drug delivery systems and conducted sarcopenia research. In 2009, they worked as a Chemical Engineer at Florida State University. From 1999 to 2010, they worked as an Equity Derivatives Trader at Hodge Capital. In 2013, they served as a Portfolio Manager, Strategic Initiatives at Kiva. They then transitioned to the pharmaceutical industry, working as an Engineer at Novartis Vaccines from 2010 to 2017 and at Seqirus from 2017 to 2021. At AveXis, Inc., they held the position of Engineer from 2018 to 2021. Most recently, they have joined GreenLight Biosciences in 2021, first as a Process Engineering Manager and currently as an Associate Director of Engineering.

R.S. Duncanson studied Chemical - Biomedical Engineering with a specialization in Theoretical and Mathematical Physics at Florida State University until 2010.